Fig. 1.

Antibody responses to PvMSP8 in the acute disease stage and after infection. A cross-sectional survey was used to explore the seroprevalence of the antibody response in symptomatic patients with a P. vivax infection (n = 40) and after recovery from infection for 3 (n = 35), 9 (n = 26), and 12 (n = 25) months compared to healthy controls (HC, n = 20). The filled circles represent the subjects that were used for the longitudinal analysis. The cut-off value was calculated from the mean plus 2 SDs of the OD for HC. AC, acute phase; HC, healthy controls